A gene called high mobility group A1 may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, Johns Hopkins Department of Medicine, Johns Hopkins Department of Pathology and the Johns Hopkins Institute for Cell Engineering.
Color Health announced Large Language Expert, a new AI application architecture to address challenges that prevent GenAI from becoming a trusted co-pilot in clinical decision-making.
Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.
A study presented by researchers at Fox Chase Cancer Center shows that some patients with metastatic kidney cancer receiving a combination therapy can safely stop or pause treatment after two years if they have a good response.
Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.
Patients with localized muscle-invasive bladder cancer who received radiation plus the immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical study published in Clinical Cancer Research, a journal of the AACR.
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.
Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.
A study from New York University researchers found that cancer cells work together to source nutrients from their environment—a cooperative process that was previously overlooked by scientists but may be a promising target for treating cancer. The study was published in Nature.
Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.
